Oral Delivery of Niclosamide as an Amorphous Solid Dispersion That Generates Amorphous Nanoparticles during Dissolution

Niclosamide is an FDA-approved anthelmintic that is being studied in clinical trials as a chemotherapeutic and broad-spectrum antiviral. Additionally, several other applications are currently in the preclinical stage. Unfortunately, niclosamide is a poorly water soluble molecule, with reduced oral bioavailability, which hinders its use for new indications. Moreover, niclosamide is a poor glass former; in other words, the molecule has a high tendency to recrystallize, and it is virtually impossible to generate a stable amorphous solid employing the neat molecule. Previously, our group reported the development of an amorphous solid dispersion (ASD) of niclosamide (niclosamide ASD) that generates nanoparticles during its dissolution, not only increasing niclosamide’s apparent solubility from 6.6 ± 0.4 to 481.7 ± 22.2 µg/mL in fasted state simulated intestinal fluid (FaSSIF) but also its oral bioavailability 2.6-fold in Sprague–Dawley rats after being administered as a suspension. Nevertheless, niclosamide ASD undergoes recrystallization in acidic media, and an enteric oral dosage form is needed for its translation into the clinic. In this work, we further characterized the nanoparticles that generated during the dissolution of the niclosamide ASD. Cryogenic transmission electron microscopy (Cryo-TEM) and wide-angle X-ray scattering (WAXS) revealed that the nanoparticles were amorphous and had a particle size of ~150 nm. The oral dosage forms of niclosamide ASD were formulated using commercial enteric capsules (Capsuline® and EudracapTM) and as enteric-coated tablets. The enteric dosage forms were tested using pH-shift dissolution and acid-uptake tests, using the USP type II dissolution apparatus and the disintegration apparatus, respectively. The capsules exhibited a higher percentage of weight gain, and visual rupture of the Capsuline capsules was observed. Eudracap capsules protected the formulation from the acidic media, but polymer gelling and the formation of a nondispersible plug were noted during dissolution testing. In contrast, enteric-coated tablets protected the formulation from acid ingress and maintained the performance of niclosamide ASD granules during dissolution in FaSSIF media. These enteric-coated tablets were administered to beagle dogs at a niclosamide dose of 75 mg/kg, resulting in plasma concentrations of niclosamide higher than those reported in the literature using solubilized niclosamide at a higher dose (i.e., 100 mg/kg). In summary, an enteric oral dosage form of niclosamide ASD was formulated without hindering the generation of nanoparticles while maintaining the increase in the niclosamide’s apparent solubility. The enteric-coated tablets successfully increased the niclosamide plasma levels in dogs when compared to a niclosamide solution prepared using organic solvents.

[1]  Linc Chen,et al.  Water-Resistant Drug-Polymer Interaction Contributes to the Formation of Nano-Species during the Dissolution of Felodipine Amorphous Solid Dispersions. , 2022, Molecular pharmaceutics.

[2]  Geoff G. Z. Zhang,et al.  Impact of Surfactants on the Performance of Clopidogrel-Copovidone Amorphous Solid Dispersions: Increased Drug Loading and Stabilization of Nanodroplets , 2022, Pharmaceutical Research.

[3]  Essentials of Industrial Pharmacy , 2022, AAPS Advances in the Pharmaceutical Sciences Series.

[4]  D. Needham The pH Dependence of Niclosamide Solubility, Dissolution, and Morphology: Motivation for Potentially Universal Mucin-Penetrating Nasal and Throat Sprays for COVID19, its Variants and other Viral Infections , 2021, Pharmaceutical Research.

[5]  M. Sahini,et al.  Cation–π interactions drive hydrophobic self-assembly and aggregation of niclosamide in water , 2021, RSC advances.

[6]  A. Estevez,et al.  Impact of Surfactant Selection and Incorporation on in situ Nanoparticle Formation from Amorphous Solid Dispersions. , 2021, International journal of pharmaceutics.

[7]  Hyun Jin Park,et al.  Bioanalysis of niclosamide in plasma using liquid chromatography-tandem mass and application to pharmacokinetics in rats and dogs , 2021, Journal of Chromatography B.

[8]  Ruochen Yang,et al.  Drug Release and Nanodroplet Formation from Amorphous Solid Dispersions: Insight into the Roles of Drug Physicochemical Properties and Polymer Selection. , 2021, Molecular pharmaceutics.

[9]  J. Choy,et al.  Niclosamide–Clay Intercalate Coated with Nonionic Polymer for Enhanced Bioavailability toward COVID-19 Treatment , 2021, Polymers.

[10]  M. Sudheesh,et al.  A mechanistic review on the dissolution phase behavior and supersaturation stabilization of amorphous solid dispersions , 2021, Drug development and industrial pharmacy.

[11]  Miguel O. Jara,et al.  Amorphous Solid Dispersions and the Contribution of Nanoparticles to In Vitro Dissolution and In Vivo Testing: Niclosamide as a Case Study , 2021, Pharmaceutics.

[12]  Christel A. S. Bergström,et al.  Molecular dynamics simulations reveal membrane interactions for poorly water-soluble drugs: impact of bile solubilization and drug aggregation. , 2020, Journal of pharmaceutical sciences.

[13]  Ravi P. Shah,et al.  Cross linking of poly (vinyl alcohol) films under acidic and thermal stress. , 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  Gerard R. Klinzing,et al.  The Effect of Inorganic Salt on Disintegration of Tablets with High Loading of Amorphous Solid Dispersion Containing Copovidone , 2020, Pharmaceutical Research.

[15]  Jia Zhou,et al.  Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential , 2020, ACS infectious diseases.

[16]  P. Langguth,et al.  Enteric Hard Capsules for Targeting the Small Intestine: Positive Correlation between In Vitro Disintegration and Dissolution Times , 2020, Pharmaceutics.

[17]  Cordula Stillhart,et al.  Formulating amorphous solid dispersions: Impact of inorganic salts on drug release from tablets containing Itraconazole-HPMC extrudate. , 2019, Molecular pharmaceutics.

[18]  G. Simpson,et al.  Characterization of Phase Transformations for Amorphous Solid Dispersions of a Weakly Basic Drug upon Dissolution in Biorelevant Media , 2019, Pharmaceutical Research.

[19]  R. Löbenberg,et al.  Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities. , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[20]  L. Benning,et al.  A template-free and low temperature method for the synthesis of mesoporous magnesium phosphate with uniform pore structure and high surface area. , 2019, Nanoscale.

[21]  K. Kawakami,et al.  Cryo-TEM and AFM Observation of the Time-Dependent Evolution of Amorphous Probucol Nanoparticles Formed by the Aqueous Dispersion of Ternary Solid Dispersions. , 2019, Molecular pharmaceutics.

[22]  L. S. Taylor,et al.  Congruent release of drug and polymer: A “sweet spot” in the dissolution of amorphous solid dispersions , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Anil Kane,et al.  Development of controlled release amorphous solid dispersions (CRASD) using polyvinyl acetate‐based release retarding materials: Effect of dosage form design , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  M. Mohutsky,et al.  Mechanistic understanding of the phase behavior of supersaturated solutions of poorly water‐soluble drugs , 2018, International journal of pharmaceutics.

[25]  R. Williams,et al.  Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery - An update. , 2018, International journal of pharmaceutics.

[26]  R. Premont,et al.  Niclosamide: Beyond an antihelminthic drug , 2017, Cellular Signalling.

[27]  Christel A. S. Bergström,et al.  Characterization of Solubilizing Nanoaggregates Present in Different Versions of Simulated Intestinal Fluid , 2017, The journal of physical chemistry. B.

[28]  Jeffrey M. Ting,et al.  Direct Observation of Nanostructures during Aqueous Dissolution of Polymer/Drug Particles , 2017 .

[29]  B. Aungst,et al.  Optimizing Oral Bioavailability in Drug Discovery: An Overview of Design and Testing Strategies and Formulation Options. , 2017, Journal of pharmaceutical sciences.

[30]  L. A.,et al.  Isolation, characterization using LC-ESI-QTOF, NMR and in vitro cytotoxicity assay of niclosamide forced degradation products. , 2017, Journal of pharmaceutical and biomedical analysis.

[31]  P. Leeson,et al.  Quality guidelines for oral drug candidates: dose, solubility and lipophilicity. , 2016, Drug discovery today.

[32]  W. Xu,et al.  Mechanism of Dissolution-Induced Nanoparticle Formation from a Copovidone-Based Amorphous Solid Dispersion. , 2016, Molecular pharmaceutics.

[33]  Mayur S. Dudhedia,et al.  Development of Tablet Formulation of Amorphous Solid Dispersions Prepared by Hot Melt Extrusion Using Quality by Design Approach , 2016, AAPS PharmSciTech.

[34]  Alan B. Watts,et al.  Formulating Poorly Water Soluble Drugs , 2016, AAPS Advances in the Pharmaceutical Sciences Series.

[35]  X. Ren,et al.  Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure. , 2015, Bioorganic & medicinal chemistry.

[36]  N. Hellmann,et al.  Fasted-state simulated intestinal fluid "FaSSIF-C", a cholesterol containing intestinal model medium for in vitro drug delivery development. , 2015, Journal of pharmaceutical sciences.

[37]  Bernd Meibohm,et al.  Applied Pharmacometrics (AAPS Advances in the Pharmaceutical Sciences Series) , 2015, CPT: Pharmacometrics & Systems Pharmacology.

[38]  G. Marosi,et al.  Downstream processing of polymer-based amorphous solid dispersions to generate tablet formulations. , 2015, International journal of pharmaceutics.

[39]  W. Massad,et al.  On the photooxidation of the multifunctional drug niclosamide. A kinetic study in the presence of vitamin B2 and visible light , 2015, Redox report : communications in free radical research.

[40]  N. Vadia,et al.  Development and validation of stability indicating RP-HPLC and HPTLC for determination of Niclosamide in bulk and in synthetic mixture , 2015 .

[41]  S. Shantier,et al.  STABILITY STUDIES ON NICLOSAMIDE USING DERIVATIVE SPECTROSCOPIC AND CHROMATOGRAPHIC METHODS , 2015 .

[42]  Khairi Mustafa Salem Fahelelbom,et al.  Performances of New Generation of Delayed Release Capsules , 2014 .

[43]  H. Zaazaa,et al.  Kinetic study and mechanism of Niclosamide degradation. , 2014, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[44]  Waseem Kaialy,et al.  Computational predictions of glass-forming ability and crystallization tendency of drug molecules. , 2014, Molecular pharmaceutics.

[45]  S. Onoue,et al.  Microenvironmental pH-modification to improve dissolution behavior and oral absorption for drugs with pH-dependent solubility , 2014, Expert opinion on drug delivery.

[46]  Dave A. Miller,et al.  The use of inorganic salts to improve the dissolution characteristics of tablets containing Soluplus®-based solid dispersions. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[47]  G. Mooter,et al.  The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate. , 2012, Drug discovery today. Technologies.

[48]  A. Bansal,et al.  Investigation of atypical dissolution behavior of an encapsulated amorphous solid dispersion. , 2011, Journal of pharmaceutical sciences.

[49]  M. Brewster,et al.  Pharmaceutical applications of cyclodextrins: basic science and product development , 2010, The Journal of pharmacy and pharmacology.

[50]  Feng Qian,et al.  Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development. , 2010, Journal of pharmaceutical sciences.

[51]  Alan M. Smith,et al.  Polymer film formulations for the preparation of enteric pharmaceutical capsules , 2010, The Journal of pharmacy and pharmacology.

[52]  A. Rajabi-Siahboomi,et al.  Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies , 2010, Drug development and industrial pharmacy.

[53]  A. Rajabi-Siahboomi,et al.  Evaluation of recent advances in continuous film coating processes , 2010, Drug development and industrial pharmacy.

[54]  Martin Kuentz,et al.  Study of a Standardized Taurocholate- Lecithin Powder for Preparing the Biorelevant Media FeSSIF and FaSSIF , 2010 .

[55]  S. Badawy,et al.  Microenvironmental pH modulation in solid dosage forms. , 2007, Journal of pharmaceutical sciences.

[56]  M. D. de Villiers,et al.  Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. , 2005, International journal of pharmaceutics.

[57]  A. P. Lötter,et al.  Comparison of the Physical and Chemical Stability of Niclosamide Crystal Forms in Aqueous Versus Nonaqueous Suspensions , 2004, Drug development and industrial pharmacy.

[58]  C. Lipinski Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[59]  A. Gürsoy,et al.  Preparation and Properties of Tablets Prepared from Furosemide-PVP Solid Dispersion Systems , 1988 .